Seyed Mohammad Mahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, Kamyar Khorsand, Samira Masoumi, Seyed Abbas Pakmehr, Mahsa Asadi Anar, Nahid Samadi, Mohadeseh Poudineh, Mohammad Rahmanian, Shirin Yaghoobpoor, Arash Rahimi, Fariba Arbab Mojeni, Seyedeh Zahra Banihashemian, Mina Masoodi, Komeil Aghazadeh-Habashi, Atousa Ghorbani, Arezoo Faridzadeh, Niloofar Deravi
{"title":"The influence of SGLT-2 inhibitors on lipid profiles in heart failure patients: a systematic review and meta-analysis.","authors":"Seyed Mohammad Mahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, Kamyar Khorsand, Samira Masoumi, Seyed Abbas Pakmehr, Mahsa Asadi Anar, Nahid Samadi, Mohadeseh Poudineh, Mohammad Rahmanian, Shirin Yaghoobpoor, Arash Rahimi, Fariba Arbab Mojeni, Seyedeh Zahra Banihashemian, Mina Masoodi, Komeil Aghazadeh-Habashi, Atousa Ghorbani, Arezoo Faridzadeh, Niloofar Deravi","doi":"10.62347/AAPZ2726","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Sodium-glucose cotransporter two inhibitors can reduce cardiovascular events by modulating lipid profiles in patients with heart failure, irrespective of diabetes status. In this study, we aimed to assess the effects of SGLT-2 inhibitors on the lipid profiles of patients with heart failure via a meta-analysis.</p><p><strong>Methods: </strong>The PubMed, Scopus, Web of Science, and Google Scholar databases were searched up to 2023 to retrieve relevant article titles, abstracts, and full texts. STATA software was used to conduct the meta-analysis.</p><p><strong>Result: </strong>The Forest plot of fasting blood sugar levels in patients receiving SGLT-2 inhibitors differed significantly from those the in control group (mean difference = -0.08, 95% CI [-0.13, -0.02], P < 0.05). Analysis of lipid profile parameters, including total cholesterol, triglyceride, HDL, and LDL in patients with HF receiving SGLT-2 inhibitors, did not show a notable difference from the control group (P > 0.005). However, the mean difference was towards the reduction of LDL, cholesterol, and triglycerides and showed an increase in HDL levels. Egger's test for publication bias revealed some publication bias (P < 0.05).</p><p><strong>Conclusion: </strong>Our topic analysis did not reveal any notable alterations in the lipid profile. To arrive at a more definite agreement, further research on subjects with heart failure is necessary because there is currently insufficient evidence.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"295-305"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744213/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/AAPZ2726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aim: Sodium-glucose cotransporter two inhibitors can reduce cardiovascular events by modulating lipid profiles in patients with heart failure, irrespective of diabetes status. In this study, we aimed to assess the effects of SGLT-2 inhibitors on the lipid profiles of patients with heart failure via a meta-analysis.
Methods: The PubMed, Scopus, Web of Science, and Google Scholar databases were searched up to 2023 to retrieve relevant article titles, abstracts, and full texts. STATA software was used to conduct the meta-analysis.
Result: The Forest plot of fasting blood sugar levels in patients receiving SGLT-2 inhibitors differed significantly from those the in control group (mean difference = -0.08, 95% CI [-0.13, -0.02], P < 0.05). Analysis of lipid profile parameters, including total cholesterol, triglyceride, HDL, and LDL in patients with HF receiving SGLT-2 inhibitors, did not show a notable difference from the control group (P > 0.005). However, the mean difference was towards the reduction of LDL, cholesterol, and triglycerides and showed an increase in HDL levels. Egger's test for publication bias revealed some publication bias (P < 0.05).
Conclusion: Our topic analysis did not reveal any notable alterations in the lipid profile. To arrive at a more definite agreement, further research on subjects with heart failure is necessary because there is currently insufficient evidence.
背景和目的：钠-葡萄糖共转运蛋白2抑制剂可以通过调节心力衰竭患者的脂质谱来减少心血管事件，而与糖尿病状态无关。在这项研究中，我们旨在通过荟萃分析评估SGLT-2抑制剂对心力衰竭患者脂质谱的影响。方法：检索截至2023年的PubMed、Scopus、Web of Science和谷歌Scholar数据库，检索相关文章标题、摘要和全文。采用STATA软件进行meta分析。结果：SGLT-2抑制剂组空腹血糖Forest图与对照组有显著差异（平均差异= -0.08,95% CI [-0.13, -0.02], P < 0.05）。接受SGLT-2抑制剂的HF患者的血脂参数分析，包括总胆固醇、甘油三酯、HDL和LDL，与对照组没有显着差异（P < 0.05）。然而，平均差异是低密度脂蛋白、胆固醇和甘油三酯的降低，高密度脂蛋白水平升高。Egger's发表偏倚检验显示有一定的发表偏倚（P < 0.05）。结论：我们的主题分析没有发现任何显著的血脂变化。为了达成更明确的共识，有必要对心力衰竭患者进行进一步的研究，因为目前证据不足。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
